Carboplatin in Oesophageal Adenocarcinoma
Author Information
Author(s): A. Steel, M.H. Cullen, P.W. Robertson, H.R. Matthews
Primary Institution: East Birmingham Hospital and Queen Elizabeth Hospital, Birmingham, UK
Hypothesis
Carboplatin may be effective in treating adenocarcinoma of the oesophagus.
Conclusion
Carboplatin appears to be ineffective as a single agent at a dose of 400 mg/m2 in this disease.
Supporting Evidence
- Carboplatin is less toxic than cisplatin and can be given to out-patients.
- Stable disease was recorded in 10 patients, but there was no response in any of the tumours.
- Two patients with liver secondaries died at 3 months.
Takeaway
The study tested a drug called carboplatin on patients with a type of throat cancer, but it didn't help them get better.
Methodology
Patients with untreated adenocarcinoma of the oesophagus received two courses of carboplatin, and their response was evaluated after treatment.
Limitations
The study had a small sample size and no responses were observed in the evaluable patients.
Participant Demographics
Fifteen male patients, median age 62, with WHO performance status 0, 1, or 2.
Statistical Information
Confidence Interval
<20% with 95% confidence
Want to read the original?
Access the complete publication on the publisher's website